Psychiatrists saw more patients and were responsible for a greater number of prescriptions in 1998.
Psychiatrists saw more patients and were responsible for a greater number of prescriptions in 1998, according to a recent report released by Newtown, PA-based Scott-Levin.
For the 12 months ending October 1998, psychiatrists received more than 58 million visits - an increase of 4% over the year before.
As a result of those consultations, they wrote 93.1 million retail prescriptions, or 1,815 prescriptions per doctor. That's 5% more prescriptions than the number psychiatrists wrote the year before. In total, psychiatrists were responsible for $5.6 billion in retail prescription sales.
"The main fact could be that psychiatrists have had a lot more attention lately from specialty sales forces. They are receiving a lot more details, mainly due to the companies' strategies," said Andrew Diefes, a marketing research analyst for Scott-Levin, when asked why psychiatrists were writing a greater volume of prescriptions.
According to Scott-Levin, the top products prescribed by psychiatrists were the same drugs that were most detailed. Prozac accounted for 8.1% of prescriptions, Zoloft received 5.4% of prescriptions and Paxil accounted for 5% of prescriptions.
By therapeutic class, the top five classes prescribed by psychiatrists were: specific neurotransmitter modulators, such as selective serotonin receptor inhibitors and selective NR inhibitors, (24.5%); seizure disorder therapies, (10.4%); antipsychotics, (9.5%); benzodiazepines, (9.3%); and similar antidepressants, (7.5%).
Sales reps made 2.6 million details to psychiatrists for the year ended October 1998, making psychiatrists the fifth most detailed group of doctors. PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.